- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03957083
Oxytocin at Elective Cesarean Deliveries: A Dose-finding Study in Women With BMI ≥ 40kg/m2
Postpartum hemorrhage (PPH) due to uterine atony is a major cause of maternal morbidity and mortality. Uterotonic drugs are used to improve the muscle tone of the uterus after birth, and these are effective at reducing the incidence of PPH. Oxytocin is the most commonly used uterotonic drug to prevent and treat PPH. Large doses of this drug are asociated with adverse effects like low blood pressure, nausea, vomiting, abnormal heart rhythms and changes on ECG. Various international bodies recommend varying and high doses of oxytocin in elective cesarean sections. A study performed at Mount Sinai Hospital showed that a much smaller dose of oxytocin is required (ED95 being 0.35IU). However, most of the women included in this study were below a body mass index (BMI) of 40kg/m2.
The investigators seek to find the best dose for patients with a BMI>40kg/m2, as a higher dose may be needed in this population to contract the uterus adequately.
Study Overview
Detailed Description
Postpartum hemorrhage (PPH) is one of the leading causes of death during childbirth and accounts for an estimated 140,000 deaths per year worldwide. The World Health Organization (WHO) recommends active management of the third stage of labor to prevent PPH, even in low risk patients. Prophylactic uterotonic drugs administered after delivery are the main element of active management of the third stage and have been demonstrated to reduce the incidence of PPH by up to 40%. Oxytocin is the most commonly used uterotonic in North America, however it has a very short duration of action and requires a continuous infusion to achieve sustained effect, with large doses associated with adverse effects like low blood pressure, nausea, vomiting, abnormal heart rhythms and changes on ECG.
The prevalence of obesity is increasing in young women and some studies have shown that obese women have higher rates of caesarean delivery compared to non-obese women. Other studies have demonstrated an increased risk of hemorrhage due to poor uterine tone in obese women. Laboratory studies show that BMI alone appears to contribute to blunted uterine muscle responses and therefore contraction responses to oxytocin in obese women.
Previous dose finding studies have excluded those women with a BMI of ≥40kgm2. Therefore, the investigators wish to perform a double-blind dose finding study using the biased coin up-and-down sequential allocation technique to determine the ED90 of oxytocin at cesarean section in those women with a BMI>40.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G1X5
- Mount Sinai Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI ≥40kg/m2
- Elective cesarean delivery under regional anesthesia
- Gestational age ≥ 37 weeks
- No known additional risk factors for postpartum hemorrhage
- Written informed consent to participate in this study
Exclusion Criteria:
- Refusal to give written informed consent
- Allergy or hypersensitivity to oxytocin
- Conditions (other than high BMI) that may predispose to uterine atony and postpartum hemorrhage such as placenta previa, multiple gestation, severe preeclampsia (as defined by SOGC guidelines (21)), eclampsia, polyhydramnios, uterine fibroids, previous history of uterine atony resulting in PPH, or bleeding diathesis.
- Hepatic, renal, and vascular disease
- Use of general anesthesia prior to the administration of the study drug
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Oxytocin 0.5IU
Patient is given 0.5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
|
Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
Other Names:
|
Active Comparator: Oxytocin 1IU
Patient is given 1IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
|
Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
Other Names:
|
Active Comparator: Oxytocin 2IU
Patient is given 2IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
|
Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
Other Names:
|
Active Comparator: Oxytocin 3IU
Patient is given 3IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
|
Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
Other Names:
|
Active Comparator: Oxytocin 4IU
Patient is given 4IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
|
Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
Other Names:
|
Active Comparator: Oxytocin 5IU
Patient is given 5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
|
Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Uterine tone 2 minutes: questionnaire
Time Frame: 2 minutes
|
Uterine tone, defined as satisfactory or unsatisfactory by the obstetrician at 2 minutes after completion of the oxytocin injection.
|
2 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hypotension: systolic blood pressure less than 80% of baseline
Time Frame: 2 hours
|
Systolic blood pressure < 80% of baseline, from drug administration until end of surgery
|
2 hours
|
Tachycardia: heart rate greater than 130% of baseline
Time Frame: 2 hours
|
Heart rate > 130% of baseline, from drug administration until end of surgery
|
2 hours
|
Bradycardia: heart rate less than 70% of baseline
Time Frame: 2 hours
|
Heart rate < 70% of baseline or a heart rate < 50bpm, from drug administration until end of surgery
|
2 hours
|
Presence of ventricular tachycardia: ECG
Time Frame: 2 hours
|
Presence of ventricular tachycardia as recorded by ECG, from drug administration until end of surgery
|
2 hours
|
Presence of atrial fibrillation: ECG
Time Frame: 2 hours
|
Presence of atrial fibrillation as recorded by ECG, from drug administration until end of surgery
|
2 hours
|
Presence of atrial flutter: ECG
Time Frame: 2 hours
|
Presence of atrial flutter as recorded by ECG, from drug administration until end of surgery
|
2 hours
|
Presence of nausea: questionnaire
Time Frame: 2 hours
|
The presence of nausea and number of episodes, from drug administration until end of surgery, as reported by the patient
|
2 hours
|
Presence of vomiting: questionnaire
Time Frame: 2 hours
|
The presence of vomiting and number of episodes, from drug administration until end of surgery
|
2 hours
|
Presence of chest pain: questionnaire
Time Frame: 2 hours
|
Any presence of chest pain, from drug administration until end of surgery, as reported by the patient
|
2 hours
|
Presence of shortness of breath: questionnaire
Time Frame: 2 hours
|
Any presence of shortness of breath, from drug administration until end of surgery, as reported by the patient
|
2 hours
|
Presence of headache: questionnaire
Time Frame: 2 hours
|
Any presence of headache, from drug administration until end of surgery, as reported by the patient
|
2 hours
|
Presence of flushing: questionnaire
Time Frame: 2 hours
|
Any presence of flushing, from drug administration until end of surgery
|
2 hours
|
Intraoperative requirement for additional uterotonic medication
Time Frame: 1 hour
|
A request made by the obstetrician performing the cesarean delivery for additional uterotonic medication, due to bleeding or poor uterine tone.
|
1 hour
|
Intravenous fluid administered during surgery
Time Frame: 2 hours
|
The total volume (ml) of fluid administered from entering the operating room to skin closure.
|
2 hours
|
Calculated estimate of blood loss
Time Frame: 24 hours
|
Blood loss will be calculated through the difference in hematocrit values assessed prior to and at the end of 48 hours after the cesarean delivery, according to the following formula: Calculated blood loss = EBV ((Pre-op Htc-Post-op Htc)/pre-op Htc). EBV (estimated blood volume) in ml: patient's weight in kg x 85 |
24 hours
|
Need for uterine massage: questionnaire
Time Frame: 20 minute
|
The obstetricians will be asked if there was any need for uterine massage beyond the initial 3 minute evaluation period following delivery.
|
20 minute
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Oxytocin
-
University of Electronic Science and Technology...Completed
-
Hillel Yaffe Medical CenterUnknownCervix; Insufficient Dilatation in LaborIsrael
-
University of NebraskaNational Institute of Mental Health (NIMH)Terminated
-
GlaxoSmithKlineCompletedPostpartum HemorrhageUnited Kingdom
-
University of Electronic Science and Technology...Recruiting
-
GlaxoSmithKlineMonash University; InVentiv CliniqueTerminatedPostpartum HemorrhageAustralia, United Kingdom
-
University Hospital, ToulouseCompleted
-
OptiNose ASUniversity of OsloCompletedHealthy Male AdultsNorway
-
Washington University School of MedicineUniversity of MichiganRecruiting
-
Wake Forest University Health SciencesNational Institute of Neurological Disorders and Stroke (NINDS)CompletedHealthy Volunteer StudyUnited States